Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors
- 1 August 2011
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (8), 2226-2237
- https://doi.org/10.1002/art.30389
Abstract
Objective Drug–drug interactions can limit the safety of colchicine for treating rheumatic diseases. Seven separate drug–drug interaction (DDI) studies were performed to elucidate the in vivo effects of concomitant treatment with colchicine and known inhibitors of cytochrome P450 3A4 (CYP3A4)/P‐glycoprotein (cyclosporine, ketoconazole, ritonavir, clarithromycin, azithromycin, verapamil ER [extended release]), and diltiazem ER) on the pharmacokinetics of colchicine. The objective was to develop colchicine‐dosing algorithms with improved safety. Methods All studies were open‐label, non‐randomized, single‐center, one‐sequence, two‐period DDI experiments, using two 0.6‐mg doses of colchicine, separated by a minimum 14‐day washout period, followed by administration of the approved on‐label regimen of known CYP3A4/P‐glycoprotein inhibitors. Plasma concentrations of colchicine, but not the reference CYP3A4/P‐glycoprotein inhibitors, were determined, and the pharmacokinetic parameters were calculated. Results The ratios of the maximum concentration and area under the curve from time 0 to infinity for colchicine plus CYP3A4/P‐glycoprotein inhibitors versus colchicine alone were >125% across all studies, with the exception of studies involving azithromycin. Significant DDIs were present when single doses of colchicine were coadministered with most of the selected CYP3A4/P‐glycoprotein inhibitors. Recommended colchicine dose reductions of 33–66% for the treatment of acute gout and 50–75% for prophylaxis were calculated for concomitant therapy with each agent, with the exception of no dose adjustment when colchicine is used in combination with azithromycin. Conclusion These studies provide quantitative evidence regarding drug interactions and necessary adjustments in the dose of colchicine if colchicine treatment is continued during therapy with multiple CYP3A4/P‐glycoprotein inhibitors. We demonstrated the need for specific reductions in the dose of colchicine when it is used in combination with 2 broadly prescribed calcium channel blockers (verapamil ER and diltiazem ER) and that the dose of colchicine does not need to be adjusted when it is used in combination with azithromycin.Keywords
This publication has 27 references indexed in Scilit:
- High versus low dosing of oral colchicine for early acute gout flare: Twenty‐four–hour outcome of the first multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison colchicine studyArthritis & Rheumatism, 2010
- A Novel Human Multidrug Resistance GeneMDR1VariantG571A(G191R) Modulates Cancer Drug Resistance and Efflux TransportJournal of Pharmacology and Experimental Therapeutics, 2008
- Is P-glycoprotein (ABCB1) a phase 0 or a phase 3 colchicine transporter depending on colchicine exposure conditions?Toxicology and Applied Pharmacology, 2006
- Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux TransportersInternational Journal of Toxicology, 2006
- Tetraparesis associated with colchicine is probably due to inhibition by verapamil of the P-glycoprotein efflux pump in the blood-brain barrierBMJ, 2005
- Two Probable Cases of Serious Drug Interaction Between Clarithromycin and ColchicineSouthern Medical Journal, 2005
- Fatal Interaction between Clarithromycin and Colchicine in Patients with Renal Insufficiency: A Retrospective StudyClinical Infectious Diseases, 2005
- Obesity, Weight Change, Hypertension, Diuretic Use, and Risk of Gout in MenArchives of Internal Medicine, 2005
- DOES COLCHICINE WORK? THE RESULTS OF THE FIRST CONTROLLED STUDY IN ACUTE GOUTAustralian and New Zealand Journal of Medicine, 1987
- Effect of prophylactic colchicine therapy on leukocyte function in patients with familial mediterranean feverArthritis & Rheumatism, 1976